Scienmag

JULY 1, 2021

Almost twenty years ago, the process of RNA silencing was discovered in plants, whereby small fragments of RNA inactivate a portion of a gene during protein synthesis.

RNA 60

RNA Protein Research Gene 60

Drug Discovery World

OCTOBER 7, 2022

To investigate the immune environment that surrounds these chemotherapy-resistant tumours, the researchers employed multiple and novel complementary technologies looking at proteins and genes on both pre-treatment and post-treatment breast cancer tissue. Developing immunotherapies for high-risk breast cancer patients.

Research 52

Research Immune Response Gene Bioinformatics 52

Drug Discovery World

JULY 29, 2022

Scientists modelling the cancer-suppressing p53 gene identify how the 20 different molecules unique to elephants get activated for increased sensitivity and response against carcinogenic conditions – with implications for cancer treatments in humans.

Gene 52

Gene DNA Protein Genetics 52

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

APRIL 14, 2023

DDW Editor Reece Armstrong speaks to Nautilus Co-Founder and Chief Scientist Parag Mallick , about the company’s recent collaboration which aims to uncover the proteins that could be behind a rare and fatal childhood cancer. To do this, Nautilus will useits protein analysis platform to provide TGen with data on the proteins involved in DPIG.

Protein 52

Protein Genome Genomics DNA 52

Drug Discovery World

APRIL 14, 2023

He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Genetics 52

Genetics Research Medicine Clinical Research 52

pharmaphorum

SEPTEMBER 14, 2020

While there may be just under 20,000 confirmed protein coding genes, it turns out that much of the genome outside of these genes is also important in regulating how the genome is controlled. Most current technology actually focuses on looking at the bits of the genome that produce proteins.

Genome 118

Genome Genomics Medicine Gene 118

Drug Discovery World

FEBRUARY 6, 2023

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

Drug Discovery World

JULY 11, 2023

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

NOVEMBER 30, 2023

This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It The next presentation attended in this track was the keynote presentation, which was given by Kate Smith, PhD, Head of UK Protein & Cell Sciences at GSK. GSK has developed high-throughput mammalian and E.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Jonathan Fisher, PhD, Group Leader, University College London, on: ‘Local secretion of immune active proteins for direct and bystander tumour killing’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 15, 2022

If you want to order gene-length sequences, rather than short oligos for PCR, the waiting times are around two or three weeks at least. Modern advances in DNA synthesis, however, have made it possible to leverage gene-to- antibody production platforms where input candidate DNA sequences can be turned into purified antibodies.

DNA 98

DNA Drugs Antibody Engineer 98

XTalks

DECEMBER 13, 2023

This impressive growth can be attributed to Fulgent’s distinctive chemistries and advanced proprietary bioinformatics pipeline, which have been instrumental in fueling the company’s rapid advancement in recent years. Alpine Immune Sciences has recently announced an augmentation in its R&D investment. million and $38.8 million and $33.9

Genetics 111

Genetics Vaccination Vaccine DNA 111

XTalks

NOVEMBER 7, 2022

Such information can reveal details about tumor staging, tumor progression, heterogeneity, gene mutations and clonal evolution. The first option is to design a personalized small NGS gene panel based on the somatic mutations that were detected in the patient, and this can be used for monitoring disease progression.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Roots Analysis

AUGUST 28, 2022

Recent advances in multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging, in combination with bioinformatics and biostatistics, have been translated into several popular bioanalytical platforms, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry.

Genome 52

Genome Genomics RNA Genome Project 52

Drug Discovery World

APRIL 21, 2023

Additionally, Dr Gianni will share insights on the use of these new tools in target validation and how they might revolutionise the drug discovery paradigm.

Doctors 52

Doctors Doctor Genetics In-Vitro 52

The Pharma Data

JANUARY 10, 2021

I actually think neuroscience is going to heat up in 2021,” said Ben Zeskind , co-founder and CEO of Immuneering , which is using bioinformatics and computational biology to develop new drugs in this space, along with oncology and immuno-oncology. Moving on From the Amyloid Hypothesis. “I Same with Alzheimer’s.

Vaccination 52

Vaccination Vaccine Regulation Drugs 52